Bicycle Therapeutics receives fast track designation from FDA for BT8009

Bicycle Therapeutics announced that the FDA has granted fast track designation, or FTD, to Bicycle’s BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer. BT8009 is a potential first in class Bicycle Toxin Conjugate targeting Nectin-4, a protein that is highly expressed in urothelial cancer, or UC, and other solid tumors.